Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption

Competing Interest Statement

N.W. receives research funding from Novo Nordisk and has consulted for ArgoBio studio. A.O.'D.-L. is on the scientific advisory board for Congenica, was a paid consultant for Tome Biosciences, Ono Pharma USA Inc. and at present for Addition Therapeutics, and received reagents from PacBio to support rare disease research. All other authors declare no competing interests.

Funding Statement

Patients included in this study were diagnosed through multiple studies including Plan France Médecine Génomique 2025 (PFMG2025); DEFIDIAG, a study sponsored by INSERM and supported by The French Ministry of Health in the framework of French initiative for genomic medicine (PFMG2025); Solve-RD, a project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 779257; Deutsche Forschungsgemeinschaft (DFG) - Project number 458099954 to Ch.De. and Project number 37144118 to R.A.J and So.N.; Inserm as part of the 2022 MESSIDORE program (project number Inserm-MESSIDORE No.19); the European Joint Programme on Rare Diseases GENOMIT I6478-B by the Austrian Science Fund FWF; by the Centre for Population Genomics (Garvan Institute of Medical Research and Murdoch Children's Research Institute) and was funded in part by a National Health and Medical Research Council investigator grant (2009982) and the Medical Research Future Fund (MRFF) Genomics Health Futures Mission (2008820). Part of this study was supported by the "Priority Research Programme on Rare Diseases" of the French Investments for the Future Programme, project MultiOmixCare. The Australian Undiagnosed Diseases Network (UDN-Aus) acknowledges financial support from the Australian Government's Medical Research Future Fund (MRFF grant reference number MRF2007567). Cases identified by the Broad Center for Mendelian Genomics (AODL and SLS) were supported by the National Human Genome Research Institute (NHGRI) grants UM1HG008900 and U01HG0011755. The Care4Rare Canada Consortium is funded by Genome Canada and the Ontario Genomics Institute (OGI-147), the Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Genome Quebec, and Children's Hospital of Eastern Ontario Foundation. K.B. is supported by a CIHR Foundation Grant (FDN-154279) and a Tier 1 Canada Research Chair in Rare Disease Precision Health. G.D.G is supported by a CIHR Fellowship award (MFE-491710). The research at Boston Children's Hospital was supported by the BCH Children's Rare Disease Collaborative and the Robinson Fund for Transformative Research in Epilepsy, and A.M.D. was supported by a BCH Office of Faculty Development/Basic & Clinical Translational Research Executive Committees Faculty Career Development Fellowship. The research conducted at the Murdoch Children's Research Institute was supported by the Victorian Government's Operational Infrastructure Support Program. Genome sequencing in Spanish patients was supported by the Undiagnosed Rare Diseases Program of Catalonia (URDCat; PERIS SLT002/16/00174) from the Autonomous Government of Catalonia; the Biomedical Research Networking Center on Rare Diseases (CIBERER, ACCI19-759); the Hesperia Foundation (Royal House of Spain), and La Marató de TV3 Foundation with project 202006-30 to C.C. and A.P. and the Instituto de Salud Carlos III co-funded by the Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, una manera de hacer Europa (FIS PI20/00758 and PI23/01090) to C.C., and IMPACT-Genomica (IMP/00009) to A.P. We thank the CERCA Program/Generalitat de Catalunya for institutional support. This study uses resources generated by the ENCODE Consortium and Thomas Gingeras lab (CSHL). N.W. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant no. 220134/Z/20/Z), a research prize from the Lister Institute. Y.C. is supported by a studentship from Novo Nordisk. P.Z.'s work was being supported by Stiftung Michael through the assistance of the Canger-Janz-Fellowship. TSB was supported by ZonMw Vidi, grant 09150172110002), and acknowledges support from Stichting 12q. KÕ was supported by Estonian Research Council grants PRG471 and PRG2040. SLS was supported by a Manton Center for Orphan Disease Research postdoctoral fellowship. SB received a grant from la Fondation pour la Recherche médicale (EQU202203014861).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study complies with the ethical standards of each of the participating countries. An informed consent was obtained for all patients included in this study from their parent or legal guardian. A specific consent form was obtained from the families who consented to publication of photographs. Patient/participant/samples were pseudonymized for the genetic study at each participating center. We collected information on the sex (but not gender) of the patients from the patients' clinical file. The study has received the approval of the ethics committee of University Hospital Essen (24-12010-BO). For methylation analysis, DNA from all individuals (patients and controls) had been collected previously in the context of genetic analysis in a medical setting, following signature of a written, informed consent that includes a query on the use of leftovers in a research setting. Healthy controls consisted in individuals without NDD who underwent pre-symptomatic testing for other conditions and were found to be non-carriers or unaffected relatives of patients with a genetic disease, among non- carriers of pathogenic variants. Samples used for the methylation study were stored within the genetics biological collection of the CRBi, Rouen, France, declared as DC 2008-711 (access authorization no. MCRBi/2024/02). The analysis of methylation profiles based on previously stored DNA in these conditions was approved by the CERDE ethics committee (notification no. E2023-13) from the Rouen University Hospital. Researchers and clinicians from participating centers contributing either data or intellectual input were involved at all stages of the study from design, implementation, drafting, and revising the manuscript, and are coauthors of the article.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes